Welcome to our dedicated page for McKesson Corporation news (Ticker: MCK), a resource for investors and traders seeking the latest updates and insights on McKesson Corporation stock.
McKesson Corporation (symbol: MCK) is a leading healthcare services and information technology company, dedicated to improving the business of healthcare globally. Ranked 11th on the Fortune 500 list, McKesson collaborates with a diverse range of stakeholders including payers, hospitals, physician offices, pharmacies, pharmaceutical companies, and other entities across the healthcare spectrum. The company's mission is to foster healthier organizations that deliver superior care to patients in every setting.
McKesson is one of the top three pharmaceutical wholesalers in the United States, engaging in the sourcing and distribution of branded, generic, and specialty pharmaceutical products. Their extensive client base includes retail chains, independent pharmacies, mail-order pharmacies, hospital networks, and healthcare providers. Alongside Cencora and Cardinal Health, McKesson commands over 90% of the US pharmaceutical wholesale industry.
Beyond the US, McKesson's reach extends to Canada, where they are involved in pharmaceutical wholesale and distribution. Additionally, McKesson supplies medical-surgical products and equipment to healthcare facilities and offers a range of technology solutions tailored for pharmacies.
McKesson's comprehensive service offerings include pharmaceutical and medical-surgical supply management, healthcare information technology solutions, and business and clinical services. The company is committed to helping its customers enhance their financial, operational, and clinical performance, ultimately aiming to deliver better patient care.
Recent achievements include strategic partnerships and innovative projects that continue to position McKesson as a key player in the healthcare industry. Their ongoing projects are designed to streamline operations and improve efficiency across the board, ensuring that healthcare providers can focus on patient care.
For more details on McKesson Corporation, visit www.mckesson.com.
McKesson announced the election of Dr. Deborah Dunsire to its board of directors, effective June 3, 2024. Dr. Dunsire, with over 30 years of experience in the biopharmaceutical and oncology sectors, will also serve on the Compensation and Talent Committee and Finance Committee. She recently retired as CEO of H. Lundbeck A/S and has held leadership roles at XTuit Pharmaceuticals, FORUM Pharmaceuticals, and Millennium: The Takeda Oncology Company.
Meanwhile, current board members Linda Mantia and Susan Salka will not stand for re-election at the 2024 Annual Meeting of Shareholders. The board size will reduce to 11 members, 10 of whom will be independent. McKesson's board chair, Donald Knauss, expressed gratitude for their contributions.
McKesson (NYSE: MCK) has reported its fiscal 2024 fourth quarter financial results. The earnings conference call for investors will be held today, May 7th. The company's financial results, along with a slide presentation, can be accessed on McKesson's Investor Relations website.